Predictive value of TRAF6 expression in the efficacy of radiotherapy for esophageal cancer

Abstract

Abstract:

ObjectiveTo investigate the predictive value of tumor necrosis factor receptor-associated factor 6 (TRAF6) expression in the efficacy of radiotherapy for patients with esophageal squamous cell carcinoma (ESCC).MethodsA total of 278 patients with ESCC received radical radiotherapy in Yixing Cancer Hospital of Jiangsu Province from February 2012 to March 2015 were included. The expression of TRAF6 in esophageal cancer tissue was detected by immunohistochemistry. The correlations between the expression of TRAF6 and clinicopathological features, short-term efficacy of radiotherapy and survival of ESCC patients were investigated.ResultsAll the patients were divided into positive expression group (n=194) and negative expression group (n=84). TRAF6 expression was significantly associated with TNM stage and lymph node metastasis in ESCC patients (χ²=13.670,P<0.001;χ²=45.497,P<0.001). The total effective rate of radiotherapy in the TRAF6 positive expression group was 62.9% (122/194), which was significantly lower than that of TRAF6 negative expression group (92.9%, 78/84), and the difference was statistically significant (χ²=26.085,P<0.001). The median survival time of TRAF positive expression group was 51 months, while that of TRAF negative expression group was not reached, and the difference of survival curve between the two groups was statistically significant (χ²=7.952,P=0.005). Further analysis showed that higher TNM stage, lymph node metastasis and positive expression of TRAF6 increased the risk of death in ESCC patients (HR=1.96, 95%CI: 1.39-2.76;HR=1.72, 95%CI: 1.29-2.29;HR=2.31, 95%CI: 1.57-3.39).ConclusionPatients with TRAF6 positive expression of ESCC have low radiotherapy sensitivity. TRAF6 may be a new target for diagnosis and treatment of ESCC patients, which provides a new idea for the diagnosis, treatment and prognosis of ESCC.

Key words:Esophageal neoplasms,Radiotherapy,Radiation tolerance,Tumor necrosis factor receptor-associated factor 6

Zhu Guomin, Pan Wei, Zhang Yufeng, Chen Hui. Predictive value of TRAF6 expression in the efficacy of radiotherapy for esophageal cancer[J]. Journal of International Oncology, 2020, 47(8): 462-466.

Figures/Tables3

临床病理特征	例数	阳性	阴性	χ²值	P值
性别
男	149	102(68.5)	47(31.5)	0.268	0.604
女	129	92(71.3)	37(28.7)
年龄(岁)
<65	140	94(67.1)	46(32.9)	0.933	0.334
≥65	138	100(72.5)	38(27.5)
肿瘤部位
颈段	19	13(68.4)	6(31.6)
胸上段	103	71(68.9)	32(31.1)	0.189	0.979
胸中段	123	86(69.9)	37(30.1)
胸下段	33	24(72.7)	9(27.3)
分化程度
高分化	45	36(80.0)	9(20.0)
中分化	136	94(69.1)	42(30.9)	2.922	0.232
低分化	97	64(66.0)	33(34.0)
TNM分期
Ⅰ、Ⅱ期	59	34(57.6)	25(42.4)	13.670	<0.001
Ⅲ、Ⅳ期	219	177(80.8)	42(19.2)
淋巴结转移
是	178	149(83.7)	29(16.3)	45.497	<0.001
否	100	45(45.0)	55(55.0)

因素	β值	SE值	Wald值	P值	HR值	95%CI
性别(男/女)	0.332	0.241	5.716	0.456	1.39	0.96~1.83
年龄(每增加5岁)	0.483	0.276	6.341	0.386	1.62	0.91~2.36
肿瘤部位(胸段/颈段)	0.563	0.287	6.835	0.336	1.76	0.95~2.68
分化程度(高/中~低分化)	0.789	0.283	9.852	0.131	2.20	0.84~3.60
TNM分期(Ⅲ~Ⅳ/Ⅰ~Ⅱ)	0.673	0.213	14.834	0.022	1.96	1.39~2.76
淋巴结转移(是/否)	0.543	0.197	13.992	0.030	1.72	1.29~2.29
TRAF6(高/低表达)	0.837	0.214	18.277	0.006	2.31	1.57~3.39

References15

[1]	Pishgar F, Haj-Mirzaian A, Ebrahimi H, et al. Global, regional and national burden of testicular cancer, 1990-2016: results from the Global Burden of Disease Study 2016[J]. BJU Int, 2019,124(3):386-394. DOI: 10.1111/bju.14771. doi:10.1111/bju.14771pmid:30953597
[2]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015,65(2):87-108. DOI: 10.3322/caac.21262. doi:10.3322/caac.21262pmid:25651787
[3]	Zheng H, Ren W, Pan X, et al. Role of intravoxel incoherent motion MRI in early assessment of the response of esophageal squamous cell carcinoma to chemoradiotherapy: a pilot study[J]. J Magn Reson Imaging, 2018,48(2):349-358. DOI: 10.1002/jmri.25934. doi:10.1002/jmri.25934pmid:29297204
[4]	Lagergren J, Smyth E, Cunningham D, et al. Oesophageal cancer[J]. Lancet, 2017,390(10110):2383-2396. DOI: 10.1016/S0140-6736(17)31462-9. doi:10.1016/S0140-6736(17)31462-9pmid:28648400
[5]	Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer[J]. Nat Rev Dis Primers, 2017,3:17048. DOI: 10.1038/nrdp.2017.48. doi:10.1038/nrdp.2017.48pmid:28748917
[6]	Han Q, Yao F, Zhong C, et al. TRAF6 promoted the metastasis of esophageal squamous cell carcinoma[J]. Tumour Biol, 2013,35(1):715-721. DOI: 10.1007/s13277-013-1098-z. doi:10.1007/s13277-013-1098-zpmid:24026882
[7]	Liu H, Tamashiro S, Baritaki S, et al. TRAF6 activation in multiple myeloma: a potential therapeutic target[J]. Clin Lymphoma Myeloma Leuk, 2012,12(3):155-163. DOI: 10.1016/j.clml.2012.01.006. doi:10.1016/j.clml.2012.01.006pmid:22440007
[8]	石琳, 李丽. TRAF6在卵巢癌组织中的表达及临床意义[J]. 中国免疫学杂志, 2015,31(12):1695-1698. DOI: 10.3969/j.issn.1000-484x.2015.12.024.
[9]	韩春, 任雪姣, 王澜, 等. 钡餐造影结合CT评价食管癌放疗近期疗效的研究[J]. 中华放射肿瘤学杂志, 2013,22(1):26-29. DOI: 10.15912/j.cnki.gocm.2015.18.018. doi:10.3760/cma.j.issn.1004-4221.2013.01.008
[10]	Urashima M, Beroukhim R, Mermel CH, et al. The landscape of somatic copy-number alteration across human cancers[J]. Nature, 2010,463(7283):899-905. DOI: 10.1038/nature08822. pmid:20164920
[11]	章国良, 孙元水, 唐智亮, 等. TRAF6表达与胃癌患者营养状况及预后的关系[J]. 中华肿瘤防治杂志, 2017(14):951-954. DOI: 10.16073/j.cnki.cjcpt.2017.14.001.
[12]	邓卓峰, 周峥, 齐娟. 舌癌组织肿瘤坏死因子受体相关因子6表达变化及临床意义[J]. 山东医药, 2017(8):95-97. DOI: 10.3969/j.issn.1002-266X.2017.08.029.
[13]	Zhou CF, Li XB, Sun H, et al. Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells[J]. IUBMB Life, 2012,64(9):775-782. DOI: 10.1002/iub.1066. doi:10.1002/iub.1066
[14]	Rong Y, Wang D, Wu W, et al. TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells[J]. Med Oncol, 2014,31(11):260. DOI: 10.1007/s12032-014-0260-9. doi:10.1007/s12032-014-0260-9pmid:25252821
[15]	Zhang XL, Dang YW, Li P, et al. Expression of tumor necrosis factor receptor-associated factor 6 in lung cancer tissues[J]. Asian Pac J Cancer Prev, 2014,15(24):10591-10596. DOI: 10.7314/apjcp.2014.15.24.10591. doi:10.7314/apjcp.2014.15.24.10591pmid:25605144